Neuroblastoma samples from patients with low and intermediate risk (INSS/INRG) were grouped together for this retrospective study and high-risk patients were defined as in Table 1 (Stage 4 > 18 months plus all MYCN-amplified cases). Here, MYCN is linked to neuroblastoma.